Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. - Wikidata - awgldk - TriplyDB

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

http://www.wikidata.org/entity/Q40284731

about

Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo.DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer.Transcriptional regulation of oncogenic protein kinase Cϵ (PKCϵ) by STAT1 and Sp1 proteins.Organogenesis and tumorigenesis: insight from the JAK/STAT pathway in the Drosophila eye PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.Development of laser ionization techniques for evaluation of the effect of cancer drugs using imaging mass spectrometry LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer.Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities.The mechanism of DAB2IP in chemoresistance of prostate cancer cells.Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Potential use of custirsen to treat prostate cancer.Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.Clusterin and chemoresistance.Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.Clusterin, a gene enriched in intestinal stem cells, is required for L1-mediated colon cancer metastasis.Versican is a potential therapeutic target in docetaxel-resistant prostate cancer The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence.HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

P2860

Q21090788-9DF3B5DF-61AB-40E2-A1C9-17A2FC1D3559 Q26796704-8D52D2C0-65CB-4F19-8BF5-A0BB717632B8 Q27304386-C17EBDA6-49DA-408D-B7B9-607F44C5179D Q28075965-BD8AE1D7-2E4C-4142-A317-5DE72E237360 Q30412002-651D30F6-05D4-42D7-9CEF-97FE5FAA61AA Q33556178-9F32556C-3302-4C86-B624-55A0C2B18553 Q33724512-72DCA324-CF1A-435C-9DC2-AF7977FACA80 Q33805578-98A3C284-1664-4D32-B7DC-7F8074BA0310 Q33838280-A69E0FED-E114-4156-A312-7C238C825327 Q33888667-E89F849E-7795-4408-BFB3-8C49FFD18CDD Q34275385-F3559366-001B-4C01-9A3B-BA9F98DA702D Q35068026-7066D9F0-246F-4A67-B677-445B93789D79 Q35082989-BD31A2C0-86A3-4F1B-A926-BC20C242D9BF Q35087685-CF1E43A8-4D78-430B-A08B-562534FB9430 Q35195744-EF3E7185-8C55-4982-A50C-1098A10C616B Q35895033-722CC4B5-3F15-4FDC-9B02-7BA11EA21763 Q35963384-68894095-041A-4AE3-86A7-F9A243F7D366 Q36184999-9210EE3E-6531-4150-9E19-44577154697E Q36245211-D329FE45-7F88-4A36-AC70-D96481EE3670 Q36725756-D4A3426D-7B76-424A-BB68-6F13F2D2B38B Q36739411-1263626F-1E33-4B97-81F7-EE70D7911E59 Q36860976-65C1C91B-E7E7-49FE-A37D-385B6B4F01D8 Q36975969-13A02090-0D1C-4F86-BA1E-A4F0ED8C3D68 Q37089543-E528817E-4485-4F3B-B807-E75F8007015C Q37120262-9EBD3745-7388-440E-BB6A-7D04B09FF741 Q37295655-A86822EB-84E9-43CC-8B0E-85C77CA9929F Q37418671-7BFACA02-0DA1-42BF-A23A-1A0D1BE93C00 Q37418683-8F019863-4F9C-40F0-8379-4ABFF9807D42 Q37625188-F4599D3D-1F96-4C9D-80A2-2FEF5CC1B9AA Q37718444-56A0A859-82C5-4C0D-801C-590A512EA01F Q37888027-D0D8293D-7F88-42FA-9565-31702BC90EF6 Q37968599-933C3CD0-54B8-439E-BAA1-EB882187DF62 Q38259980-FC954AC1-FF94-4577-9963-29B00DB5FCE6 Q38464804-5FCB3F70-D184-4E0F-8EE7-DBD9F12A3D90 Q38575004-9CD771AE-A711-4E2C-9FD9-F499E85F40CE Q38704252-AADDADB1-FC7F-424C-A978-3C3C265F0C36 Q38793802-9533E792-A180-46A3-9A85-D7E51B099938 Q38825651-91F4347C-6341-4543-8AB4-513FBBEECA34 Q38827721-377816F3-8175-48A0-9D35-09CE7DD6F63B Q38832738-4E737E02-C3AE-4522-8CE9-7EA400208A63

P2860

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

http://www.wikidata.org/entity/Q40284731

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

@en

type

label

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

@en

prefLabel

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

@en

P1433

Q40284731-8311F0E3-3A44-4244-BF3F-12E936147708

P1476

Q40284731-B3636761-8DA1-45E8-93C4-053463E84BDB

P2093

Q40284731-5A2FA3E4-5572-4602-8BD9-DA74533A50B5

Q40284731-611B6EC0-C533-4BBB-94E9-29648D9C0AA1

Q40284731-67A1C5E8-661D-4B80-BEF7-AFE12D27F1E9

Q40284731-6931C9B8-17D2-4762-834E-3D58535171C4

Q40284731-94F4748A-77FC-4C88-80D3-6F672B75E2DE

Q40284731-9CE918C2-3FE3-4457-8D73-4EB63A900685

Q40284731-A34B0902-9C21-41EF-8701-2C1E3244BB68

Q40284731-D3C2DD3D-4F48-4669-AC2F-8AD03A26683F

Q40284731-F9F20FAF-3F2D-45FD-9D72-485072857C94

P2860

Q40284731-0D551663-C2B0-4D4D-A6D4-1CFE0884D360

Q40284731-1ECD5AEF-158F-4CA4-884C-89DD67D18FB8

Q40284731-206E30DC-8964-4619-934A-DBE340A3B897

Q40284731-224EBB1F-EEE2-4551-8C72-9192C9586C92

Q40284731-2F33F3FC-6F4A-4271-A449-3938C9D08456

Q40284731-2F5E86CF-3640-4AD6-87F0-7F0C92F65DEC

Q40284731-333C7B17-C1B7-41F3-B90B-26625D65A39E

Q40284731-3C3B143E-24D6-427A-9156-6B3A3E5F5375

Q40284731-3D2297B7-5C77-461C-9CB5-3E95AA6AC487

Q40284731-478A44BF-BB6E-476B-BAE0-915447896A36

P2888

Q40284731-40212EAC-A955-498C-AC20-9CC49A129008

P304

Q40284731-3D0A12B3-7638-43B2-AE09-22695D9C96E0

P31

Q40284731-DB9C1737-BC58-417F-9481-61FD8439B873

P356

Q40284731-41022863-B0F9-4413-8D02-7DAF8B71125F

P407

Q40284731-3E3A6661-F3BD-4EA8-896C-ED490085FC26

P433

Q40284731-24B0F6A9-1EDF-442C-A37A-1FF9A1EF5E82

P478

Q40284731-C249DC8E-0687-436F-AF62-9DD73F8C48F1

P577

Q40284731-841D676B-D228-4F32-9187-1777284D7742

P5875

Q40284731-14644E14-97A7-4BC7-B1FE-9EA45F837881

P6179

Q40284731-88C7933B-BF2E-4046-A51B-3595F9D1C859

P698

Q40284731-6394B70E-3943-4213-9368-0E862626BC4D

P356

P1433

P1476

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

@en

P2093

B Zhong

http://www.w3.org/2001/XMLSchema#string

D A Sallman

http://www.w3.org/2001/XMLSchema#string

D L Gilvary

http://www.w3.org/2001/XMLSchema#string

J Pow-Sang

http://www.w3.org/2001/XMLSchema#string

J Y Djeu

http://www.w3.org/2001/XMLSchema#string

S G Patterson

http://www.w3.org/2001/XMLSchema#string

S Wei

http://www.w3.org/2001/XMLSchema#string

T Yeatman

http://www.w3.org/2001/XMLSchema#string

X Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The biochemistry of apoptosis

STATs and gene regulation

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Apoptosis in cancer.

STAT proteins and transcriptional responses to extracellular signals.

Clusterin/apolipoprotein J in human aging and cancer.

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

Cancer epidemiology in the last century and the next decade.

Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.

P2888

P304

6113-6122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1209632

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7129654

http://www.w3.org/2001/XMLSchema#string

P6179

1025903837

http://www.w3.org/2001/XMLSchema#string

P698

16652143

http://www.w3.org/2001/XMLSchema#string